Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.
Sequence-based transcriptional profiling reveals unexpected transcriptome complexity in Arabidopsis thaliana and an enhanced gene catalog to facilitate genome annotation.
Diagnosis has traditionally been overshadowed by new drug discoveries. But the expansion of molecular diagnostics is creating new careers for researchers in many fields.
